DUBLIN, March 21, 2022 /PRNewswire/ -- The "Cell and Gene Therapy Bioassay Services Market by Type of Therapy, Therapeutic Area, Scale of Operation and Geography: Industry Trends and Global Forecasts, 2021-2030" report has been added to ResearchAndMarkets.com's offering.

This report features an extensive study of the current landscape and the likely future potential of cell and gene therapy bioassay service providers, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field.

Given the various advantages of cell and gene therapies and their ability to address the underlying causes of serious clinical conditions, the preference for such therapeutic modalities has increased over the years. As a result, several cell and gene therapies have been developed and approved for the treatment of a wide range of disease indications. In fact, at the time of this report's publication, more than 30 such therapies had been approved and over 1,200 therapeutic leads are under evaluation in different stages.

Owing to their rising popularity, these upcoming advanced therapeutic products are on the verge of becoming one of the highest valued therapeutic segments within the biopharmaceutical industry. Having said that, as is the case for all biological products, the development of cell and gene therapies is a complex, challenging and cost intensive process. Outsourcing is, therefore, a preferred operational model, with cell and gene therapy innovators relying heavily on specialty contract service providers to handle various aspects of their product development and manufacturing operations. In fact, over three quarters of the biopharmaceutical companies prefer to outsource their operations to the contract service providers and a large part of their expenditure goes to outsourcing services.

Amongst the various operations, the outsourcing of analytical testing services, including environment testing, bioanalytical testing, analytical testing, chemistry and stability testing, method development and validation, and product characterization, has witnessed significant rise in recent years.

The rising demand for outsourcing bioanalytical services has prompted the emergence of several contract research organizations that claim to offer bioassay services for cell and gene therapies. These companies usually have relatively more experience and are well equipped with the instruments and technological platforms to offer both pre-developed and customized bioassays.

In fact, these companies assist in bringing out the maximum efficiency of study design by offering several cost benefits and reducing the associated timelines. Given the benefits of outsourcing the bioassay services and the ongoing efforts of service providers to further improve / expand their respective offerings, we believe that the cell and gene therapy bioassay services market is likely to evolve at a steady pace, till 2030.

In addition to other elements, the study includes:

Key Questions Answered

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. MARKET LANDSCAPE

5. COMPANY COMPETITIVENESS ANALYSIS 5.1. Chapter Overview 5.2. Methodology 5.3. Key Parameters 5.4. Competitiveness Analysis: Companies Offering Cell and Gene Therapy Bioassay Services in North America 5.5. Competitiveness Analysis: Companies Offering Cell and Gene Therapy Bioassay Services in Europe and Asia-Pacific

6. CELL AND GENE THERAPY BIOASSAY SERVICE PROVIDERS IN NORTH AMERICA: COMPANY PROFILES 6.1. Chapter Overview 6.2. CCRM 6.2.1. Company Overview 6.2.2. Cell and Gene Therapy Bioassay Service Portfolio 6.2.3. Recent Developments and Future Outlook 6.3. Nexelis 6.3.1. Company Overview 6.3.2. Cell and Gene Therapy Bioassay Service Portfolio 6.3.3. Recent Developments and Future Outlook 6.4. Pacific BioLabs 6.4.1. Company Overview 6.4.2. Cell and Gene Therapy Bioassay Service Portfolio 6.4.3. Recent Developments and Future Outlook 6.5. PPD Laboratories 6.5.1. Company Overview 6.5.2. Cell and Gene Therapy Bioassay Service Portfolio 6.5.3. Recent Developments and Future Outlook 6.6. WuXi Advanced Therapies 6.6.1. Company Overview 6.6.2. Cell and Gene Therapy Bioassay Service Portfolio 6.6.3. Recent Developments and Future Outlook

7. CELL AND GENE THERAPY BIOASSAY SERVICE PROVIDERS IN EUROPE AND ASIA-PACIFIC: COMPANY PROFILES 7.1. Chapter Overview 7.2. AnaBioTec 7.2.1. Company Overview 7.2.2. Cell and Gene Therapy Bioassay Service Portfolio 7.2.3. Recent Developments and Future Outlook 7.3. Intertek Pharmaceutical Services 7.3.1. Company Overview 7.3.2. Cell and Gene Therapy Bioassay Service Portfolio 7.3.3. Recent Developments and Future Outlook 7.4. Lonza 7.4.1. Company Overview 7.4.2. Cell and Gene Therapy Bioassay Service Portfolio 7.4.3. Recent Developments and Future Outlook 7.5. Porton Bio 7.5.1. Company Overview 7.5.2. Cell and Gene Therapy Bioassay Service Portfolio 7.5.3. Recent Developments and Future Outlook

8. MARKET TREND ANALYSIS

9. GLOBAL EVENT AND STRATEGIC INITIATIVE ANALYSIS

10. CASE STUDY: MARKET LANDSCAPE OF CELL AND GENE THERAPIES 10.1. Chapter Overview 10.2. Cell Therapy Market 10.2.1. T-Cell Immunotherapies: Development Pipeline 10.2.1.1. Analysis by Type of Product 10.2.2. CAR-T Cell Therapies: Development Pipeline 10.2.2.1. Analysis by Phase of Development 10.2.2.2. Analysis by Therapeutic Area 10.2.2.3. Analysis by Type of Developer 10.2.2.4. Key Industry Players: Analysis by Number of CAR-T Cell Therapies in Development 10.2.3. TCR-based Therapies: Development Pipeline 10.2.3.1. Analysis by Phase of Development 10.2.3.2. Analysis by Therapeutic Area 10.2.3.3. Analysis by Type of Developer 10.2.3.4. Key Industry Players: Analysis by Number of TCR-based Therapies in Development 10.2.4. TIL-based Therapies: Development Pipeline 10.2.4.1. Analysis by Phase of Development 10.2.4.2. Analysis by Therapeutic Area 10.2.4.3. Analysis by Type of Developer 10.2.4.4. Key Industry Players: Analysis by Number of TIL-based Therapies in Development 10.3. Gene Therapy Market 10.3.1. Gene Therapy Market: Clinical and Commercial Pipeline 10.3.1.1. Analysis by Phase of Development 10.3.1.2. Analysis by Therapeutic Area 10.3.2. Gene Therapy Market: Development Pipeline 10.3.2.1. Analysis by Phase of Development 10.3.2.2. Analysis by Therapeutic Area

11. LIKELY PARTNERS FOR CELL THERAPY BIOASSAY SERVICE PROVIDERS 11.1. Chapter Overview 11.2. Scope and Methodology 11.3. Potential Strategic Partners for Cell Therapy Bioassay Service Providers 11.3.1. Likely Partner Opportunities for Stem Cell Therapy Bioassay Service Providers 11.3.2. Likely Partner Opportunities for CAR-T Therapy Bioassay Service Providers 11.3.3. Likely Partner Opportunities for Dendritic Cell Therapy Bioassay Service Providers 11.3.4. Likely Partner Opportunities for Tumor Cell Therapy Bioassay Service Providers 11.3.5. Likely Partner Opportunities for NK Cell Therapy Bioassay Service Providers

12. LIKELY PARTNERS FOR GENE THERAPY BIOASSAY SERVICE PROVIDERS 12.1. Chapter Overview 12.2. Scope and Methodology 12.3. Potential Strategic Partners for Gene Therapy Bioassay Service Providers 12.3.1. Likely Partner Opportunities in North America 12.3.2. Likely Partner Opportunities in Europe 12.3.3. Likely Partner Opportunities in Asia-Pacific

13. MARKET FORECAST AND OPPORTUNITY ANALYSIS

14. CONCLUSION

15. EXECUTIVE INSIGHTS

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

For more information about this report visit https://www.researchandmarkets.com/r/5d7pa0

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Visit link:
Global Cell and Gene Therapy Bioassay Services Market to 2030 - by Type of Therapy, Therapeutic Area, Scale of Operation and Geography - PR Newswire